Tonight's NephJC Tweetchat is all about aPLA2R

aPLA2R is the first blood test specifically for nephrotic syndrome. It has recently been licensed by the FDA and we want to have an open and frank discussion on how this test may be used in clinical medicine. To aid in this discussion we will be looking at two papers.

The first was highlighted by CJASN's eJC and was covered summarized by Joel Topf and his Fellow, Bilal Saleem:

The second article was published this past Spring in NDT. It is an industry sponsored trial of ACTH for the treatment of membranous nephropathy. Swapnil Hiremath summarized it for #NephJC

And additionally here is a link to the KDIGO Glomerulonephritis Recommendations.

Please join us on Twitter at 9pm Eastern Daylight. Use the hashtag #NephJC.